
Lab to pay $758,000 in kickback case; fungal compound shows promise against brain cancer; losing sleep over climate change – Morning Medical Update
Key Takeaways
- NEXT Molecular Analytics faces a $758,000 settlement for allegedly disguising kickbacks as consulting fees, affecting federal healthcare programs.
- MIT's synthesis of verticillin A allows for the development of derivatives effective against diffuse midline glioma, a challenging pediatric brain cancer.
The top news stories in medicine today.
A Virginia-based clinical laboratory will pay at least $758,000 to resolve federal allegations that it funneled illegal kickbacks to physicians and marketers to generate test referrals.
MIT chemists have, for the first time, created verticillin A in the lab — a notoriously complex fungal molecule that has intrigued cancer researchers for decades. With reliable access to the compound, the team was able to design sturdier versions that Dana-Farber scientists then tested in diffuse midline glioma (DMG), a devastating childhood brain cancer with limited treatment options. Some of these derivatives were strikingly effective at killing DMG cells, particularly those driven by high EZHIP expression.
While the work, published in the
Nighttime heat may become a significant public health stressor, according to a large analysis from the Keck School of Medicine of USC, published in
West Coast residents experienced nearly triple the sleep loss seen in other regions. Extrapolating these trends, researchers estimate Americans could lose 8.5–24 hours of sleep annually by 2099, amplifying risks for cardiovascular, pulmonary and mental health complications.
Newsletter
Stay informed and empowered with Medical Economics enewsletter, delivering expert insights, financial strategies, practice management tips and technology trends — tailored for today’s physicians.















